The fastest-growing and largest of the 20 sized Pharmaceuticals markets in Middle East, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $1.5 Bn | $14.8 Bn | 25.9% | 2 |
| 2 | Cell Based Immunotherapy | $664 Mn | $5.7 Bn | 24% | 90 |
| 3 | Cannabidiol (CBD) | $882 Mn | $4.5 Bn | 17.8% | 0 |
| 4 | Cannabis | $1.4 Bn | $5.3 Bn | 14.5% | 0 |
| 5 | Atopic Dermatitis Drugs | $449 Mn | $1.6 Bn | 13.2% | 5 |
| 6 | Oncology/Cancer Drugs | $7.1 Bn | $17.4 Bn | 9.4% | 62 |
| 7 | Anti-Aging | $3.5 Bn | $8.4 Bn | 9.1% | 1 |
| 8 | Diabetes Management | $3.1 Bn | $6.8 Bn | 8.1% | 27 |
| 9 | Alzheimer Drugs | $200 Mn | $425 Mn | 7.8% | 5 |
| 10 | Contraceptives Drugs | $1 Bn | $2.1 Bn | 7.8% | 0 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $7.1 Bn | $17.4 Bn | 9.4% | 62 |
| 2 | Anti-Aging | $3.5 Bn | $8.4 Bn | 9.1% | 1 |
| 3 | Diabetes Management | $3.1 Bn | $6.8 Bn | 8.1% | 27 |
| 4 | Gastrointestinal Drugs | $2.2 Bn | $3.7 Bn | 5.6% | 23 |
| 5 | Asthma & COPD Drugs | $2 Bn | $3.2 Bn | 5% | 9 |
| 6 | Biosimilars | $1.5 Bn | $14.8 Bn | 25.9% | 2 |
| 7 | Cannabis | $1.4 Bn | $5.3 Bn | 14.5% | 0 |
| 8 | HIV Drugs | $1.2 Bn | $2.3 Bn | 6.8% | 0 |
| 9 | Contraceptives Drugs | $1 Bn | $2.1 Bn | 7.8% | 0 |
| 10 | Cancer Supportive Care Drugs | $992 Mn | $1.7 Bn | 5.7% | 11 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running, in UAE, Saudi Arabia.
Biosimilars grows fastest, at 25.9% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (24%).
Oncology/Cancer Drugs is the largest, worth about $7.1 Bn in 2023 and $17.4 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.